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Abstract 
Objective: Intensive care unit acquired weakness (ICUAW) is a common complication of 
critical illness and can have significant effects upon functional status and quality 
of life. As part of preliminary work to inform the design of an randomized trial of a 
complex intervention to improve recovery from critical illness, we sought to 
identify pharmacological interventions which may play a role in this area. 
Data Sources: We systematically reviewed the published literature relating to pharmacological 
intervention for the treatment and prevention of ICUAW. 
Study Selection: We searched Medline, Embase, CINAHL+, Web of Science and both US and 
European trial registries up to July 2014 alongside reviews and reference lists from 
populations with no age or language restrictions. We included studies that 
reported a measure of muscle structure or physical function as an outcome 
measure. We estimated pooled odds ratios (OR) and 95% confidence intervals (CI) 
using data extracted from published papers or where available, original data 
provided by the authors. Assessment of bias was performed using the Cochrane 
Collaboration’s risk of bias tool. 
Data Synthesis: Ten studies met the inclusion criteria. The current body of evidence does not 
support the use of any pharmacological agent in this setting although maintaining 
euglycemia may reduce the incidence of critical illness polyneuropathy. 
Conclusions: At present no pharmacological intervention can be recommended to prevent or 
treat ICUAW. Further research is required into this field including into more novel 
agents such as myostatin inhibitors. Challenges in the conduct of research in this 
area are highlighted. 
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Introduction 
Patients who survive significant periods of critical illness may suffer long lasting reductions in their 
quality of life, much of which can be attributed to muscle weakness (1). Weakness caused by critical 
illness is termed ‘intensive care unit acquired weakness’ (ICUAW) and has been defined by consensus as 
‘clinically detected weakness in critically ill patients in whom there is no plausible etiology other than 
critical illness’ (2). It is a common complication which prolongs both hospital and intensive care unit 
(ICU) stay and the duration of mechanical ventilation (3). 
At present, there is an imprecise understanding of the mechanisms of ICUAW. It appears weakness may 
result from abnormalities of the peripheral nervous system, peripheral musculature or a combination of 
the two (4). Critical illness polyneuropathy (CIP) is a symmetrical condition affecting the limbs, 
particularly the lower extremities (4). Weakness is most pronounced in proximal muscles but can involve 
the respiratory musculature and impede weaning from mechanical ventilation (5). Proposed 
mechanisms of CIP include injury and subsequent degeneration due to microcirculatory dysfunction that 
may be aggravated by hyperglycemia, sodium channel inactivation or mitochondrial dysfunction. 
Mitochondrial dysfunction is also implicated in critical illness polymyopthy (CIM), a primary disease of 
muscle which may be clinically indistinguishable from CIP. Histopathology reveals selective loss of thick 
filaments in muscle, reflecting a combination of myosin loss and muscle necrosis (6). There is evidence 
to suggest overlap between CIP and CIM with CIM carrying a better prognosis (7). 
Risk factors for ICUAW were recently reviewed (3). Sepsis, inflammation and multiple organ failure all 
appear particularly relevant to development of this syndrome, with hyperglycemia likely to be a 
significant risk factor for CIP (8). Studies exploring the role of glucocorticoids and neuromuscular 
blockers in ICUAW have reported inconsistent results. Inactivity is a possible risk factor but the case for 
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an independent causative effect has not yet been made (7). Despite mechanistic advances, effective 
pharmacological treatments are lacking, and treatment is supportive. 
The primary research question of this study was to ask ‘is there any evidence from randomized 
controlled trials (RCT) to support the use of any particular pharmacological intervention in the 
prevention or treatment of ICUAW?’ 
Materials and Methods 
Protocol and registration 
This systematic review is reported according to the Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses guidelines (9). 
Eligibility criteria and data sources 
Sources included a range of biomedical databases including grey literature sources. We searched 
MEDLINE and EMBASE (via OVID), Cochrane, Web of Science, CINAHL+, the European (EUDRACT) and 
American (www.clinicaltrials.gov) trial registries in July 2014. The search strategies were designed to 
identify randomized trials of pharmacological interventions used in critically ill patients (or survivors) 
that employed physical function, muscle function, muscle strength, or muscle mass (or equivalent) as 
outcome measures. An example of the search strategy used for Medline is included in the Supplemental 
Digital Content - Appendix 1.  We screened the reference lists of the included articles for relevant 
publications not retrieved in the initial search. All citing articles and related references were also 
screened using the Web of Science tool. No language or age restrictions were imposed. Studies 
considered were published between 1946 and July Week 4 2014 were included. 
Study selection and inclusion criteria 
Two reviewers (SJS and RN) screened articles at both the title/abstract and full text stages. 
Disagreements were resolved by discussion with a third reviewer (DMG) (see Figure 1). Randomized and 
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quasi-randomized, comparative interventional studies of intensive care patients or intensive care 
survivors were considered. We included studies that reported on a measure of physical function, muscle 
strength, muscle bulk or physical mobility. We included both direct (e.g. grip strength) and indirect (e.g. 
lean body mass) measures. We also retrieved systematic reviews of such studies. Studies remained in 
the review at the title and abstract screening stage if there was not enough information in the title and 
abstract on which to exclude them.  
Data collection process  
A dedicated extraction tool was adapted from the Cochrane Collaboration and was used to extract 
relevant data; this is included in Supplementary Digital Content - Appendix 2. Data extraction was carried 
out by a single reviewer (SJS). Only published data were extracted; however, authors were contacted by 
e-mail if verification of data was necessary. Where numerical values of mean and standard deviation 
results were not supplied within published papers, the author, where available, was contacted by email. 
Where the information was still not obtained, enlarged-scale visual estimation was undertaken using 
the figures in the published studies (10). 
Data items  
We recorded the study location and the recruitment dates to detect duplicate publications. We 
recorded the nature of the intervention including timing, the study setting (e.g. intensive care unit, 
hospital ward, or rehabilitation unit), age and outcome measure. Performance of formal meta-analysis 
was not carried out due to the heterogeneity of outcome measures and study populations. 
Risk of bias assessment 
Two reviewers (SJS and RN) independently assessed risk of bias in individual studies using the Cochrane 
Collaboration Risk of Bias tool (11). Using the tool, risk of bias in key domains was assessed in each study  
and given an “low”, “unclear” or “high” risk of bias for each. Disagreements were resolved by discussion 
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with a third reviewer (DMG). Studies were graded as a “low” overall risk of bias where the individual risk 
in each domain (sequence generation, allocation concealment, blinding, incomplete outcome data and 
selective outcome reporting) was deemed to be low, as “high” where the risk of bias was deemed to be 
high in one or more of these domains and similarly “unclear” where the risk was deemed unclear in one 
or more of these domains. (11) 
Secondary Analysis 
Due to the low number of papers identified by the primary question of the review, and the lack of any 
definitive treatment of any of the therapies tested in these trials, we performed a secondary analysis of 
the articles identified in the initial search. During this analysis, all other study designs were included with 
the inclusion and exclusion criteria otherwise remaining the same. These additional studies were 
analysed using GRADE methodology (12). The purpose of this secondary review was to identify other 
treatments that might be considered in the formulation of a trial intervention, even if the level of 
evidence was lower than that of the primary review question. 
Results 
Study selection 
Full details of the study selection process are shown in Figure 1. After de-duplication, 13,057 references 
were retrieved. An additional 9 articles were identified from the reference lists of included studies. Full 
text articles were retrieved for 51 studies. Thirty-seven were excluded at the full text stage (see Figure 1 
for reasons). A further 5 trials were excluded as they involved duplicate study populations of other 
retrieved publications and one further publication discarded as it was an interval analysis of 
subsequently reported trial which had also been retrieved and excluded. Another publication was a 
systematic review from which relevant publications were extracted from the reference list (8). The 
remaining 10 studies that were eligible were published between 1996 and 2012. Full details including 
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sample size, duration of follow-up, outcome measure(s) and a synopsis of relevant results are shown in 
Supplementary Digital Content - Table 1. Interventions were broadly divided into the categories below. 
Results are reported as mean (95% confidence intervals) unless otherwise stated. 
Oxandrolone 
Oxandrolone, an anabolic steroid which promotes growth of muscle mass, has been used in a single trial 
including 45 patients who had suffered severe thermal injury (13). Participants received nutritional 
supplementation with or without the addition of oxandrolone 20 mg per day upon admission to a burn 
rehabilitation unit (13). Oxandrolone was discontinued when at least 80% of the involuntary weight loss 
that had occurred during the acute burn period had been restored. The primary outcome measure was 
the rate at which body mass was regained with the percentage of lean body mass a secondary outcome. 
Patients receiving oxandrolone regained weight faster than those who received nutrition alone with a 
mean increase of 1.5 (1.38,1.62) vs. 0.7 kg (0.62,0.78) at four weeks, p < 0.05. Lean body mass at 
discharge was greater in those who received oxandrolone when measured at discharge from the 
rehabilitation unit [76 (74.37,77.63) vs. 71% (69.75,72.25) , p < 0.05]. This difference was maintained at 
six months after discontinuation of oxandrolone. Lost lean mass was not restored in the nutrition alone 
group by six months; at this time point, the control group had gained on average 4.1 kg (3.57,4.63) from 
their discharge weight whereas the oxandrolone group had gained an additional 2.8 kg (2.37,3.23). No 
data was provided on exercise or other rehabilitation undertaken. The overall risk of bias in this study 
was deemed to be unclear; although a significant clinical effect was reported, missing detail pertaining 
to most of the important sources of bias make the internal validity of this trial impossible to assess and 
we were unable to successfully contact the authors concerned. 
Euglycemia 
As hyperglycemia is thought to be a significant risk factor for CIP, the effect of insulin to maintain 
euglycemia has been investigated (14). Furthermore, insulin itself has anabolic effects (15). Two trials 
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examining the use of supplemental insulin were included in this review (16, 17). In the first, Mikaeili and 
colleagues randomized 40 medical ICU patients to insulin therapy to maintain euglycemia of 80-140 
mg/dL vs. a less restrictive regimen to maintain 180-200 mg/dL (17). Their primary outcome measure 
was the incidence of CIP as detected by electrophysiological study with the duration of mechanical 
ventilation a secondary outcome. Rates of CIP were significantly lower in the euglycemic group [10 (-
3.15,23.15) vs. 45% (23.2,66.8), p = 0.01]. The duration of mechanical ventilation was also reduced with 
tighter glycemic control [9.72 (8.04-11.4) vs. 14.05 days (10.48,17.62), p = 0.04). The lack of blinding may 
have introduced performance bias although investigators blinded to treatment allocation carried out 
the outcome assessment. 
The second study of insulin therapy was performed in 8 patients following major abdominal resection 
for cancer (16). Patients received conventional (to maintain levels of 149-200 mg/dL) versus intensive 
insulin therapy (to maintain 79-124 mg/dL) on ICU for 24 hours on the first and second days after 
elective surgery using a cross over design. All patients received total parenteral nutrition (TPN) from the 
first day post-operatively. Their primary outcome measures were the rates of skeletal muscle protein 
synthesis and degradation, leucine oxidation, glutamine de novo synthesis and dimethylarginine 
production. Rates of skeletal muscle protein synthesis were considered relevant to our review. Tighter 
glycemic control was associated with greater muscle protein synthesis (as determined by radio-isotope 
assay of glutamine uptake and leucine loss) and a less negative nitrogen balance [inferred from 
phenylalanine balance -3 (-5.08,-0.92) vs. -11 nmol/100mL/min (-13.08,-8.92), p < 0.05]. The clinical 
sequelae of these results were not explored and minimal detail was provided regarding the degree of 
post-operative organ dysfunction or clinical course, hence the generalizability and utility of this data is 
questionable. Rates of hypoglycemia were not reported. As with the previous study, blinding of the 
clinical team to the treatment allocation was not possible introducing an unavoidable source of 
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performance bias. Furthermore, the outcome assessors were also un-blinded, introducing a risk of 
detection bias. Therefore, whilst interesting, these findings were considered to be at high risk of bias. 
Growth Hormone 
Anabolic hormone therapy has been utilized in 3 trials comparing treatment with recombinant human 
growth hormone (rhGH) versus placebo on the intensive care unit including a total of 552 patients (10, 
18). One publication included data from two parallel trials (10). In the first trial, a Swedish study, a mean 
dose of 0.43 IU/kg was given for a period of 12 days to 20 patients who had failed to wean from 
mechanical ventilation after at least 7 days (18). The primary outcome measure was actually mortality 
but lean body mass and muscle strength were secondary outcomes considered relevant to our review. 
Lean body mass increased in the rhGH group [0.8 (-0.38,1.98) vs. -1.1 kg (-2.08,-0.12), p < 0.03] but no 
significant effects were seen on peripheral muscle function assessed by sequential electrical stimulation 
of adductor pollicis, the cumulative time spent on a mechanical ventilator during the 12 day study 
period or the rate of weaning (see Supplementary Digital Content - Table 1 for the relevant summary 
outcome measures). The article did not include sufficient detail to adequately assess risk of bias.   
A subsequent publication described two parallel Finnish and European multi-national trials in which a 
mean dose of 0.3 IU/kg of rhGH was administered for up to 21 days to patients on ICU after cardiac 
surgery, abdominal resection, major trauma or in whom there was a diagnosis of Acute Respiratory 
Distress Syndrome (ARDS) (10). Relevant secondary outcome measures were grip strength, exercise 
tolerance and self-reported fatigue. Both trials reported a significant excess of in-hospital mortality with 
the use of rhGH [Finnish trial: 39% versus 20%, relative risk of death 1.9 (1.3,2.9}, p < 0.001; multi-
national trial: 44% versus 18%, relative risk of death 2.4 (1.6,3.5) p < 0.001). Given this strong signal of 
harm, further analysis of functional improvement was deemed inappropriate. 
Gamrin and colleagues randomized 20 critically ill patients on a surgical ICU to treatment with rhGH at 
0.3 IU/kg/day or placebo for 5 days after which they measured the fractional synthesis rate of muscle 
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and performed biopsies of the quadriceps muscle (19). All patients received parenteral nutrition; 
supplementary enteral nutrition was given in small amounts to 4 patients in the rhGH group and 8 
controls. The primary effect variables were the protein content of skeletal muscle (measured as alkali-
soluble protein) and the rate of muscle protein synthesis. rhGH was associated with an increased 
protein content [+207% (-26.92,+440.92), p < 0.05] and increased muscle protein synthesis but the 
variability of response was high. The clinical utility of these observations was also not explored. Overall, 
the risk of bias was felt to be high in this study; treating clinicians were not blinded although during 
preparation and analysis, investigators were. Protocol violations also occurred in 3 participants. 
Propranolol 
Propanolol may attenuate the hypermetabolic state seen in ICU and thus reduce the catabolic response 
(20). Herndon and colleagues randomized 25 pediatric burn patients to propranolol at a mean dose of 
1.05 ± S.D. 0.15 mg/kg every 4 hours targeting a 20% reduction in heart rate from the average of the 
preceding day (21). Treatment was initiated 5 days after initial burn excision and continued for a 2 week 
period. Patients received conventional enteral feeding via naso-duodenal tube. Primary and secondary 
outcome measures were not specifically stated as thus; however, relevant outcome measures included 
fat-free (i.e. lean) body mass and fractional synthesis rates of skeletal muscle inferred by phenylalanine 
uptake. Those receiving propranolol demonstrated less reduction in their lean body mass [-1 (-
7.60,+5.60) vs. -9% (-16.43,-1.57), p = 0.003], results which were maintained until full healing and 
discharge from hospital. Propranolol was strongly anabolic and increased the fractional synthetic rate of 
muscle [0.337 (0.20,0.47) vs. 0.142 μmol/100 mL/min (0.07,0.22), p = 0.07). No patient required a 
prolonged period of mechanical ventilation in this study and the degree of organ dysfunction was not 
reported. The risk of bias was judged to be high: only 22/25 patients underwent evaluation of body 
composition due to technical issues with the scanning equipment over a 3 month period and the 
radioisotope study of a single patient was excluded from the analysis due to a failed study. 
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Immunoglobulin 
Weak evidence has previously suggested that early use of IgM-enriched Immunoglobulin (IVIG) may 
prevent CIP and CIM (22). This is based on a possible association of CIPNM with the pro-inflammatory 
cytokines released during critical illness, the effect of which may be attenuated by the 
immunomodulating properties of IVIG. A single trial examined the use of IVIG on the incidence of both 
CIP and CIM (23). Thirty-eight critically ill patients with multiple organ failure (MOF) secondary to 
presumed sepsis with early clinical signs of CIP or CIM were included. Patients were randomly assigned 
to either IVIG at 0.25g/kg/day or 1% human albumin solution over a period of 3 days. CIP was diagnosed 
based upon electrophysiological criteria and CIM histological evaluation. Results were quantified over a 
2 week period using a novel summative score that combined data from both of these assessments. No 
treatment effect was reported upon any of pre-specified endpoint relevant and the study was 
terminated at its first interim analysis due to futility (see Supplementary Digital Content - Table 1 for 
relevant summary measures). 
Glutamine 
Glutamine is the most abundant free amino acid in the body and is normally synthesized and stored in 
skeletal muscle, with smaller amounts made by the lungs, liver and brain (24). During sepsis and 
catabolic states, increased glutamine demands may be met in part by increasing breakdown of protein 
in skeletal muscle but glutamine deficiency can occur (25). Tjader and colleagues randomized 40 
critically ill patients with a variety of presentations to glutamine enhanced parenteral nutrition at doses 
of 0.00, 0.28, 0.57 or 0.86 g/k/day, corresponding to 0, 20, 40 or 60 g of glutamine per day for a 70 kg 
man (26). The primary outcome measures were wet muscle glutamine concentration, protein synthesis 
and protein content as alkali-free protein. Protein synthesis rates were determined by phenylalanine 
uptake radioisotope study and muscle amino acid content analysed by muscle biopsy after five days. The 
treatment successfully normalised plasma glutamine concentration in a dose-dependent way but no 
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significant difference was seen between the muscle glutamine concentrations before and after 
treatment for any subgroup (see Supplementary Digital Content - Table 1). Protein fractional synthesis 
rate did also not differ significantly between any dose-group of glutamine [2.08 (0.81,3.34) vs. 1.95 
(1.50,2.40) vs. 1.85 (1.29,2.41) vs. 1.58% (0.69,2.47), p > 0.05 for all]. The risk of bias was deemed to be 
high due to incomplete datasets; 37/40 of those randomized completed the full protocol due to clinical 
and organisational reasons. Blood and tissue samples were blinded throughout the procedure for 
sample analysis, but treatment was not blinded for attending physicians. 
Risk of bias across studies 
Overall, the risk of bias was judged to be high for eight out of the ten included studies (10, 16, 17, 19, 
21, 23, 26). For the remaining two trials the risk of bias assessment was unclear (13, 18). A full 
description of the the risk of bias assessment is shown in Table 1. 
Secondary analysis of studies not meeting eligibility for primary review 
From our secondary analysis, another 18 articles were identified (27-44). One article was excluded as it 
described an interim analysis of another included paper (44). Interventions were broadly divided into 
exogenous insulin with or without metformin, maintenance of euglycemia, exogenous growth hormone, 
insulin-like growth factor and oxandrolone. A summary of the included articles is given in  
Supplementary Digital Content - Table 2. The GRADE of evidence in the majority of studies was deemed 
low (27). Only maintenance of euglycemia demonstrated any significant effects (37, 39, 42). The GRADE 
of evidence for these trials was deemed to be moderate. 
Discussion 
Summary of evidence 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
Pharmacological Treatment of Intensive Care Unit Acquired Weakness 
Page 15 of 28 
Our review identified a number of promising treatments but given the current evidence base we are 
unable to recommend routine adoption of any particular strategy at this time. The overall risk of bias 
within the published evidence and lack of clinical correlates for studies which target surrogate measures 
such as lean body mass and protein synthesis are of particular concern. Therefore, at this time, the 
evidence does not support the utility of any pharmacological intervention in the treatment or 
prevention of ICUAW. 
Within the setting of general intensive care, only insulin therapy appears to offer any significant 
preventative effects upon CIP/CIM although the included trial was small (17). Evidence from sub-
analyses of two larger trials of intensive insulin therapy showed similar benefits but these were not 
included in our review as they were not felt to represent randomized controlled trials as only those who 
survived to seven days were screened for CIP/CIM by weekly electrophysiological examination (37, 45). 
Concerns regarding tight glycemic control have been raised in the past decade since publication of the 
Van den Berghe studies; in these original trials, rates of hypoglycemia were not insignificant, although 
morbidity associated with these events low (46, 47). In the Mikaeli study 25% of patients suffered an 
episode of hypoglycemia below 45 mg/dL requiring intervention although serious adverse events did 
not occur (17). A subsequent multi-centre randomized trial of 6,104 mixed medical and surgical patients 
demonstrated increased mortality with this approach, mainly from cardiovascular causes (48). Rates of 
hypoglycemia were significantly higher than in either of the Van den Berghe single-centre trials and a 
subsequent post-hoc analysis showed that these patients, i.e. those in whom blood sugar was less than 
2.2 mmol/L were twice as likely to die (49). Therefore, intensive insulin therapy cannot be routinely 
recommended as a strategy to combat weakness amongst critically ill patients. However, more modest 
glycemic targets may be appropriate such as those adopted by Mikaeili and colleagues if adequate 
protection against hypoglycemia can be achieved (17). Improvements in technology, in particular 
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continuous glucose monitoring and computer controlled administration of insulin may in the future 
allow this to be achieved (50). 
For patients who have suffered severe thermal injury, oxandrolone appears to offer benefits in recovery 
and maintenance of lean body mass (13). Outside of this setting, the benefits are less clear: although not 
reporting on our primary outcome measures, a study of trauma patient of oxandrolone 10 mg versus 
placebo in combination with enteral nutrition failed to show any improvement in mortality, length of 
hospital or ICU stay or duration of mechanical ventilation (51). A similar prospective, double-blind trial in 
41 ventilator-dependent surgical patients found that those who received oxandrolone spent longer on a 
ventilation (21.7 vs. 16.4 days, p = 0.03), had higher rates of re-intubation (44% vs. 13%, p = 0.02) and 
showed a non-significant trend towards more days in ICU (52). Both trials were small and single centre, 
hence further studies would be required to assess effects upon muscle function. 
Our review suggests that agents such as immunoglobulin and glutamine do not appear to offer benefit 
in this setting. It had been postulated that immunoglobulin could have a role in the prevention of 
CIP/CIM as this condition has been associated with pro-inflammatory cytokines such as TNF-α, IFN-γ, IL-
1, and IL-12 (53). It is believed that IVIG exerts its anti-inflammatory and immunomodulating properties 
through regulating such cytokines (23). Glutamine supplementation has been suggested to have a role 
in preventing undesired muscle wasting as skeletal muscle is the main producer and exporter or this 
amino acid which may be required for proper immune system functioning and subsequent deficiency 
during times of physiological stress. 
Limitations and challenges 
A major obstacle to our review was the heterogenous definition of ICUAW. Whilst entities such as CIP 
may be defined upon seemingly strict electrophysiological criteria, namely a reduction in the amplitude 
of compound muscle action (CMAP) and sensory nerve action potentials (SNAP) with normal or mildly 
reduced nerve conduction velocity, a consensus definition is lacking by how much these potentials must 
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be reduced (4). Varying degrees of fibrillation potentials and positive sharp waves can be recorded in 
both CIP and CIM and motor unit potentials may be unrecordable if consciousness is depressed; 
however, if present, they can be normal or myopathic, therefore the distinction between CIM and CIP is 
not absolute (54). Mikaeili and colleagues used a 10% reduction in CMAP/SNAP amplitude but more 
precise definitions are lacking (17). 
Our search strategy deliberately used broadly defined outcome measures so as to offer a more 
comprehensive review of current evidence. A significant limitation concerns the use of surrogate 
outcome measures, such as lean body mass or muscle bulk to infer functional improvement. This is 
clearly a large assumption. Nevertheless, trials targeting ‘harder’ functional outcomes are lacking 
outside of insulin therapy, the caveats to which have been discussed above. 
A further challenge comes from competing risk; these are events which prevent or significantly alter the 
probability a subject will experience a particular outcome (55). Mortality in ICU studies is high, hence 
death from other causes may preclude the observation of outcomes such as muscle weakness, leading 
to inaccurate estimations of effect. This is particularly problematic where interventions affect both 
competing risk and the measured outcome, such hyperglycemia as seen in the large glycemic control 
trials (46-48). Composite outcome measures can been used to account for competing risks but the 
relative contributions of each component cannot be determined (56). A more satisfactory approach 
which is infrequently employed in ICU studies is to use statistical adjustment, such as multi-state 
modelling (57). In our review, the most promising therapy is euglycemia; however, in a large studies 
(albeit one which did not not meeting the inclusion criteria for our primary analysis), ICU mortality rates 
of 21% and 12% in the intervention and control groups respectively represent competing risks not taken 
into account in the analysis (37). The effects on this therapy upon the incidence of CIP/CIN may 
therefore be overestimated. 
Avenues for Future Research 
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Whilst experimental work is ongoing into strategies to cope with ICUAW, functional decline and loss of 
strength are not unique to critical illness and may be an inevitable consequence of growing old. 
Pharmacological treatments which have been trialed in the setting of age-related sarcopenia are similar 
to those trialed in critical illness and include the administration of testosterone, growth hormone and 
supplementation of vitamin D (58-61). Results to date have been disappointing and largely reflect the 
evidence we have discussed in this review, in that whilst improvements in markers such as lean body 
mass may be seen, these do not translate into improvements in function and any benefit may be 
severely limited by serious side effects, particularly for rhGH. 
A number of more novel approaches may be of interest. Myostatin is an endogenous, TGF-β� family 
member which functions as an endogenous inhibitor of muscle growth in diverse species including 
humans (62). The myostatin gene is expressed almost exclusively in skeletal muscle cells of skeletal 
muscle embryonic development as well as in adult animals (63). In adult animals, myostatin appears to 
inhibit the activation and differentiation of satellite cells, resident stem cells in skeletal muscle that are 
critical to muscle regeneration (63). Targeted disruption of the myostatin gene in mice leads to muscle 
hypertrophy and hyperplasia, approximately doubling of muscle mass (64). The function of myostatin as 
a negative regulator of muscle growth was recently shown to be conserved in humans (65). Selective 
inhibition of this moeity may have broad clinical utility for a variety of muscle disorders including 
weakness associated with critical illness. The role of myostatin in the development of critical illness 
weakness is currently being investigated (clinicaltrials.gov reference NCT01321320). Other approaches 
including IL-6 antagonism and administration of synthetic ghrelin have also been promising in animal 
models of cachexia (66). A definitive answer on these molecules may well be with us in the next decade. 
As well as focusing upon which pharmacological agent to test, careful consideration must be given to 
study design. We urgently require consensus as to which physical outcome variables are best utilised in 
assessing weakness in ICU survivors as these vary enormously. Competing risks should also be identified 
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and planned for. Qualifying which interventions were delivered at each stage of the ICU survivor’s 
journey (i.e. during ICU, between ICU and hospital discharge and after hospital discharge) and agreeing 
on taxonomy will allow us to assess optimal timing in addition to optimal agent. Finally, consideration 
needs be given how best to account for pre-existing physical decline. It is plausible those with 
considerable neuromuscular dysfunction (whether pathological or ‘functional’) prior to the development 
of critical illness will have poorer outcomes than those without; future studies should identify and 
account for this in their design. 
Conclusions 
To date, only intensive insulin therapy has been shown to positively affect the incidence of critical illness 
acquired weakness; however, this cannot be routinely recommended due to the significant risk of 
adverse effects, particularly hypoglycemia. Clinicians should be aware that the current body of evidence 
points to a detrimental impact of uncontrolled hyperglycemia in critically ill adults and that avoidance of 
hyperglycemia may have an important impact on reducing the incidence of ICUAW but with the risk of 
hypoglycemia remains high. Further large-scale investigation into the safe provision of more moderate 
glycemic targets is warranted. Whilst novel agents show promise in small observational studies, it is 
important that key methodological challenges are addressed. Similarly, clinicians interpreting new 
studies in this area must remain mindful of these key challenges in mind when appraising new research. 
Acknowledgments 
This work has been conducted on behalf of Simon Baudouin, Danielle Bear, Bronagh Blackwood, 
Stephen Bonner, Stephen Brett, Bronwen Connollly, Rebecca Cusak, Abdel Douiri, Mark Foster, David 
Griffith, Michael Grocott, Nicholas Hart, Robert Hatch, Sallie Lamb, Nazir Lone, Danny McAuley, Kathryn 
McDowall, Judith Merriweather, Brenda O’Neill, David Parkin, Natalie Pattison, Laura Price, Stephen 
Shepherd, Lisa Salisbury, Dorothy Wade and Timothy Walsh of the Enhancing Rehabilitation after Critical 
Illness Programme trial steering group. This work is supported (SJB) by the National Institute for Health 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
Pharmacological Treatment of Intensive Care Unit Acquired Weakness 
Page 20 of 28 
Research (NIHR) Comprehensive Biomedical Research Centre at Imperial College Healthcare NHS Trust 
and Imperial College London. The views expressed are those of the authors and not necessarily the NIHR 
or the UK Department of Health.   
Declaration of interests 
All authors declare that there is no conflict of interest that could be perceived as prejudicing the 
impartiality of the paper.
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
Pharmacological Treatment of Intensive Care Unit Acquired Weakness 
Page 21 of 28 
Legends - Main Manuscript 
Table 1: Assessment of bias risk 
Figure 1: Flow chart of study assessment process 
Legends - Supplementary Digital Content 
Table 1: PICOS table of studies included in primary analysis 
Table 2: PICOS summary table of potentially interesting studies not included in the systematic review 
Appendix 1: Search strategy employed for Medline 
Appendix 2: Data extraction form 
  
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
Pharmacological Treatment of Intensive Care Unit Acquired Weakness 
Page 22 of 28 
References 
 
1. Herridge MS, Tansey CM, Matte A, et al. Functional disability 5 years after acute respiratory distress 
syndrome. The New England journal of medicine 2011;364(14):1293-1304. 
2. Stevens RD, Marshall SA, Cornblath DR, et al. A framework for diagnosing and classifying intensive 
care unit-acquired weakness. Critical care medicine 2009;37(10 Suppl):S299-308. 
3. Kress JP, Hall JB. ICU-acquired weakness and recovery from critical illness. The New England journal 
of medicine 2014;371(3):287-288. 
4. Latronico N, Bolton CF. Critical illness polyneuropathy and myopathy: a major cause of muscle 
weakness and paralysis. The Lancet Neurology 2011;10(10):931-941. 
5. Hadley JS, Hinds CJ. Anabolic strategies in critical illness. Current opinion in pharmacology 
2002;2(6):700-707. 
6. Derde S, Hermans G, Derese I, et al. Muscle atrophy and preferential loss of myosin in prolonged 
critically ill patients. Critical care medicine 2012;40(1):79-89. 
7. Latronico N. Neuromuscular alterations in the critically ill patient: critical illness myopathy, critical 
illness neuropathy, or both? Intensive care medicine 2003;29(9):1411-1413. 
8. Hermans G, De Jonghe B, Bruyninckx F, et al. Interventions for preventing critical illness 
polyneuropathy and critical illness myopathy. The Cochrane database of systematic reviews 
2009(1):CD006832. 
9. Welch V, Petticrew M, Tugwell P, et al. PRISMA-Equity 2012 extension: reporting guidelines for 
systematic reviews with a focus on health equity. PLoS Med 2012;9(10):e1001333. 
10. Takala J, Ruokonen E, Webster NR, et al. Increased Mortality Associated with Growth Hormone 
Treatment in Critically Ill Adults. New England Journal of Medicine 1999;341(11):785-792. 
11. Likis FE, Andrews JC, Fonnesbeck CJ, et al. Cochrane Risk of Bias Tool. 2014. 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
Pharmacological Treatment of Intensive Care Unit Acquired Weakness 
Page 23 of 28 
12. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence 
and strength of recommendations. BMJ 2008;336(7650):924-926. 
13. Demling RH, DeSanti L. Oxandrolone induced lean mass gain during recovery from severe burns is 
maintained after discontinuation of the anabolic steroid. Burns : journal of the International Society 
for Burn Injuries 2003;29(8):793-797. 
14. Callahan LA, Supinski GS. Hyperglycemia and acquired weakness in critically ill patients: potential 
mechanisms. Critical care 2009;13(2):125. 
15. Dimitriadis G, Mitrou P, Lambadiari V, et al. Insulin effects in muscle and adipose tissue. Diabetes Res 
Clin Pract 2011;93 Suppl 1:S52-59. 
16. Biolo G, De Cicco M, Lorenzon S, et al. Treating hyperglycemia improves skeletal muscle protein 
metabolism in cancer patients after major surgery. Critical care medicine 2008;36(6):1768-1775. 
17. Mikaeili H, Yazdchi M, Barazandeh F, et al. Euglycemic state reduces the incidence of critical illness 
polyneuropathy and duration of ventilator dependency in medical intensive care unit. Bratislavske 
lekarske listy 2012;113(10):616-619. 
18. Pichard C, Kyle U, Chevrolet JC, et al. Lack of effects of recombinant growth hormone on muscle 
function in patients requiring prolonged mechanical ventilation: a prospective, randomized, 
controlled study. Crit Care Med 1996;24(3):403-413. 
19. Gamrin L, Essen P, Hultman E, et al. Protein-sparing effect in skeletal muscle of growth hormone 
treatment in critically ill patients. Ann Surg 2000;231(4):577-586. 
20. Norbury W. Propranolol attenuates factors affecting hypermetabolism in pediatric burn patients. In: 
Critical care (London, England); 2007. p. P152 (abstract number). 
21. Herndon DN, Hart DW, Wolf SE, et al. Reversal of catabolism by beta-blockade after severe burns. 
The New England journal of medicine 2001;345(17):1223-1229. 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
Pharmacological Treatment of Intensive Care Unit Acquired Weakness 
Page 24 of 28 
22. Mohr M, Englisch L, Roth A, et al. Effects of early treatment with immunoglobulin on critical illness 
polyneuropathy following multiple organ failure and gram-negative sepsis. Intensive care medicine 
1997;23(11):1144-1149. 
23. Brunner R, Rinner W, Kitzberger R, et al. Early treatment with intravenous immunoglobulins in 
patients with critical illness polyneuropathy: A randomized controlled, doubleblinded study.  2012  
[cited 16 (Brunner, Rinner, Kitzberger, Sycha, Warszawska, Holzinger, Madl) Medical University of 
Vienna, Austria]S111]. Available from: 
http://ovidsp.ovid.com/ovidweb.cgi?T=JSPAGE=referenceD=emed10NEWS=NAN=70735247 
24. Bollhalder L, Pfeil AM, Tomonaga Y, et al. A systematic literature review and meta-analysis of 
randomized clinical trials of parenteral glutamine supplementation. Clin Nutr 2013;32(2):213-223. 
25. van Zanten AR. Glutamine and antioxidants: status of their use in critical illness. Current opinion in 
clinical nutrition and metabolic care 2015;18(2):179-186. 
26. Tjader I, Rooyackers O, Forsberg A-M, et al. Effects on skeletal muscle of intravenous glutamine 
supplementation to ICU patients. Intensive care medicine 2004;30(2):266-275. 
27. Sakurai Y, Aarsland A, Herndon DN, et al. Stimulation of muscle protein synthesis by long-term insulin 
infusion in severely burned patients.  1995  [cited 222 (Sakurai, Aarsland, Herndon, Chinkes, Pierre, 
Nguyen, Patterson, Wolfe, Brennan, Pruitt Jr., Abumrad, Fischer, Bessey, Cioffi) Metabolism Unit, 
Shriners Burns Institute, 815 Market Street, Galveston, TX 77555-1220, United States]; 3:[283-297]. 
Available from: 
http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed3&NEWS=N&AN=1995285442 
28. Debroy MA, Wolf SE, Zhang XJ, et al. Anabolic effects of insulin-like growth factor in combination with 
insulin-like growth factor binding protein-3 in severely burned adults. The Journal of trauma 
1999;47(5):904-901. 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
Pharmacological Treatment of Intensive Care Unit Acquired Weakness 
Page 25 of 28 
29. Ferrando AA, Chinkes DL, Wolf SE, et al. A submaximal dose of insulin promotes net skeletal muscle 
protein synthesis in patients with severe burns. Annals of surgery 1999;229(1):11-18. 
30. Hart DW, Herndon DN, Klein G, et al. Attenuation of posttraumatic muscle catabolism and osteopenia 
by long-term growth hormone therapy. In: Annals of surgery; 2001. p. 827-834. 
31. Hart DW, Wolf SE, Ramzy PI, et al. Anabolic effects of oxandrolone after severe burn.  2001  [cited 
233 (Hart, Wolf, Ramzy, Chinkes, Beauford, Ferrando, Wolfe, Herndon) Shriners Hospitals for 
Children, 815 Market St., Galveston, TX 77550, United States]; 4:[556-564]. Available from: 
http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed5&NEWS=N&AN=2001113998 
32. Demling RH, DeSanti L. Restoration of body weight, function, and wound healing after severe burns 
using the anabolic agent oxandrolone is not age dependent. Ostomy Wound Management 
2002;48(8):42-47. 
33. Hart DW, Wolf SE, Chinkes DL, et al. beta-blockade and growth hormone after burn. Annals of Surgery 
2002;236(4):450-457. 
34. Suman OE, Thomas SJ, Wilkins JP, et al. Effect of exogenous growth hormone and exercise on lean 
mass and muscle function in children with burns. Journal of applied physiology (Bethesda, Md : 1985) 
2003;94(6):2273-2281. 
35. Wolf SE, Thomas SJ, Dasu MR, et al. Improved net protein balance, lean mass, and gene expression 
changes with oxandrolone treatment in the severely burned. Annals of surgery 2003;237(6):801-801. 
36. Gore DC, Herndon DN, Wolfe RR, et al. Comparison of peripheral metabolic effects of insulin and 
metformin following severe burn injury.  2005  [cited 59 (Gore, Herndon, Wolfe) Department of 
Surgery, University of Texas Medical Branch, Galveston, TX 77555, United States]; 2:[316-323]. 
Available from: 
http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed7&NEWS=N&AN=2005520777 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
Pharmacological Treatment of Intensive Care Unit Acquired Weakness 
Page 26 of 28 
37. Van den Berghe G, Schoonheydt K, Becx P, et al. Insulin therapy protects the central and peripheral 
nervous system of intensive care patients. Neurology 2005;64(8):1348-1353. 
38. Przkora R, Herndon DN, Suman OE, et al. Beneficial effects of extended growth hormone treatment 
after hospital discharge in pediatric burn patients. Annals of Surgery 2006;243(6):796-803. 
39. Hermans G, Wilmer A, Meersseman W, et al. Impact of intensive insulin therapy on neuromuscular 
complications and ventilator dependency in the medical intensive care unit. In: American journal of 
respiratory and critical care medicine; 2007. p. 480-489. 
40. Przkora R, Herndon DN, Suman OE. The effects of oxandrolone and exercise on muscle mass and 
function in children with severe burns.  2007  [cited 119 (Suman) Children's Wellness and Exercise 
Center, Shriners Hospitals for Children, 815 Market St, Galveston, TX 77550, United States]; 1:[e109-
e116]. Available from: http://pediatrics.aappublications.org/cgi/reprint/119/1/e109 
http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed8&NEWS=N&AN=2007129906 
41. Branski LK, Herndon DN, Barrow RE, et al. Randomized controlled trial to determine the efficacy of 
long-term growth hormone treatment in severely burned children. Ann Surg 2009;250(4):514-523. 
42. Hermans G, Schrooten M, Van Damme P, et al. Benefits of intensive insulin therapy on neuromuscular 
complications in routine daily critical care practice: a retrospective study. Critical care (London, 
England) 2009;13(1):R5. 
43. Tuvdendorj D, Chinkes DL, Zhang X-J, et al. Long-term oxandrolone treatment increases muscle 
protein net deposition via improving amino acid utilization in pediatric patients 6 months after burn 
injury. Surgery 2011;149(5):645-653. 
44. Porro LJ, Herndon DN, Rodriguez NA, et al. Five-year outcomes after oxandrolone administration in 
severely burned children: a randomized clinical trial of safety and efficacy. Journal of the American 
College of Surgeons 2012;214(4):489-502; discussion 502-484. 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
Pharmacological Treatment of Intensive Care Unit Acquired Weakness 
Page 27 of 28 
45. Hermans G, Wilmer A, Meersseman W, et al. Impact of intensive insulin therapy on neuromuscular 
complications and ventilator dependency in the medical intensive care unit. Am J Respir Crit Care 
Med 2007;175(5):480-489. 
46. van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in critically ill patients. The 
New England journal of medicine 2001;345(19):1359-1367. 
47. Van den Berghe G, Wilmer A, Hermans G, et al. Intensive insulin therapy in the medical ICU. The New 
England journal of medicine 2006;354(5):449-461. 
48. Investigators N-SS, Finfer S, Chittock DR, et al. Intensive versus conventional glucose control in 
critically ill patients. The New England journal of medicine 2009;360(13):1283-1297. 
49. Investigators N-SS, Finfer S, Liu B, et al. Hypoglycemia and risk of death in critically ill patients. The 
New England journal of medicine 2012;367(12):1108-1118. 
50. Wernerman J, Desaive T, Finfer S, et al. Continuous glucose control in the ICU: report of a 2013 round 
table meeting. Critical care 2014;18(3):226. 
51. Gervasio JM, Dickerson RN, Swearingen J, et al. Oxandrolone in trauma patients. Pharmacotherapy 
2000;20(11):1328-1334. 
52. Bulger EM, Jurkovich GJ, Farver CL, et al. Oxandrolone does not improve outcome of ventilator 
dependent surgical patients. Ann Surg 2004;240(3):472-478; discussion 478-480. 
53. De Letter MA, van Doorn PA, Savelkoul HF, et al. Critical illness polyneuropathy and myopathy 
(CIPNM): evidence for local immune activation by cytokine-expression in the muscle tissue. J 
Neuroimmunol 2000;106(1-2):206-213. 
54. Bolton CF. Neuromuscular manifestations of critical illness. Muscle Nerve 2005;32(2):140-163. 
55. Berry SD, Ngo L, Samelson EJ, et al. Competing risk of death: an important consideration in studies of 
older adults. Journal of the American Geriatrics Society 2010;58(4):783-787. 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
Pharmacological Treatment of Intensive Care Unit Acquired Weakness 
Page 28 of 28 
56. Wolbers M, Koller MT, Stel VS, et al. Competing risks analyses: objectives and approaches. Eur Heart 
J 2014;35(42):2936-2941. 
57. Putter H, Fiocco M, Geskus RB. Tutorial in biostatistics: competing risks and multi-state models. Stat 
Med 2007;26(11):2389-2430. 
58. Hinds CJ. Administration of growth hormone to catabolic patients. Growth Hormone & Igf Research 
1999;9:71-75. 
59. Ferrando AA, Sheffield-Moore M, Yeckel CW, et al. Testosterone administration to older men 
improves muscle function: molecular and physiological mechanisms. American journal of physiology 
Endocrinology and metabolism 2002;282(3):E601-607. 
60. Latham NK, Anderson CS, Reid IR. Effects of vitamin D supplementation on strength, physical 
performance, and falls in older persons: a systematic review. Journal of the American Geriatrics 
Society 2003;51(9):1219-1226. 
61. Malafarina V, Uriz-Otano F, Iniesta R, et al. Sarcopenia in the elderly: diagnosis, physiopathology and 
treatment. Maturitas 2012;71(2):109-114. 
62. Wagner KR. Muscle regeneration through myostatin inhibition. Curr Opin Rheumatol 2005;17(6):720-
724. 
63. Bo Li Z, Zhang J, Wagner KR. Inhibition of myostatin reverses muscle fibrosis through apoptosis. 
Journal of cell science 2012;125(Pt 17):3957-3965. 
64. Lee SJ, McPherron AC. Myostatin and the control of skeletal muscle mass. Current opinion in genetics 
& development 1999;9(5):604-607. 
65. Schuelke M, Wagner KR, Stolz LE, et al. Myostatin mutation associated with gross muscle hypertrophy 
in a child. The New England journal of medicine 2004;350(26):2682-2688. 
66. Berardi E, Annibali D, Cassano M, et al. Molecular and cell-based therapies for muscle degenerations: 
a road under construction. Frontiers in physiology 2014;5:119. 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
!"#$%&'&()*+'&(
,-(./$'(*-&(
*)+/0*#/(
!"#$%&'$()
1%$$(/'"/(0'23'4(
!"#(*)
5-#$%&'&(3-(
*-*$6+3+(
!"#$')
!"#$%&'&()*+'&(,-(
7%$$(/'"/(0'23'4(
+,-./012.*3.
45,"6.7,782.9.
+,-.7:;5<82.*.
=>78.7,7>?;@,"2.(
8,/'-.*$$6(0'$'2*-/(
9%)$3#*.,-+(70,:(
;'&$3-'<(!:)*+'<(
=>?<(@5ABCDE(*-&(
@,#F0*-'(
!"#$%&'(A)
8,/'-.*$$6(
0'$'2*-/(
9%)$3#*.,-+(
70,:(0'7'0'-#'(
$3+/+(,7(3-#$%&'&(
+/%&3'+(
!"#3)
5-#$%&'&(3-(
+'#,-&*06(*-*$6+3+(
!"#$B)
Figure 1 flowchart
  
Table 2: Assessment of bias risk 
Reference Year No. Random 
sequence 
generation 
Allocation 
concealment 
Blinding of 
participants and 
personnel 
Blinding of 
outcome 
assessment 
Incomplete 
outcome data 
Selective 
reporting 
Overall risk of 
bias 
Selection Performance Detection Attrition Reporting 
Biolo 2008 16 Unclear Unclear High High Low Low High 
Brunner 2012 23 Low Low Low Low High Low High 
Demling 2003 13 Unclear Unclear Unclear Unclear Low Low Unclear 
Gamrin 2000 19 Unclear Low High Low High Low High 
Herndon 2001 21 Low Unclear Low Unclear High Low High 
Mikaeili 2012 17 Unclear Unclear High Low Low Low High 
Pichard 1996 18 Unclear Unclear Low Unclear Low Low Unclear 
Takala - 1 1999 10 Unclear Unclear Unclear Unclear High Low High 
Takala - 2 1999 10 Unclear Unclear Unclear Unclear Unclear Low High 
Tjader 2004 26 Unclear Low High Low High Low High 
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